Bibliography

Found 17 results

Filters: Keyword is Cerebrospinal Fluid [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

C

Goodkin K, Vitiello B, Lyman WD, Asthana D, Atkinson JH, Heseltine PNR, Molina R, Zheng W, Khamis I, Wilkie FL, et al. Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. Journal of NeuroVirology [Internet]. 2006 ;12(3):178-89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16877299

Guha D, Mukerji SS, Chettimada S, Misra V, Lorenz DR, Morgello S, Gabuzda D. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy. AIDS. 2019 ;33(4):615-625.

Cassol E, Misra V, Dutta A, Morgello S, Gabuzda D. Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS. 2014 ;28(11):1579-91.

Rozek W, Ricardo-Dukelow M, Holloway S, Gendelman HE, Wojna V, Meléndez LM, Ciborowski P. Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. Journal of Proteome Research [Internet]. 2007 ;6:4189-99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17929958

Perez-Valero I, Ellis RJ, Heaton RK, Deutsch R, Franklin D, Clifford DB, Collier AC, Gelman B, Marra C, McCutchan JA, et al. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 ;33(3):475-481.

Murray J, Fishman SL, Ryan EL, Eng FJ, Walewski JL, Branch AD, Morgello S. Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. Journal of Neurovirology [Internet]. 2008 ;14:17-27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18300072

Livelli A, Vaida F, Ellis RJ, Ma Q, Ferrara M, Clifford DB, Collier AC, Gelman B, Marra CM, McArthur JC, et al. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study. Lancet HIV. 2019 ;6(7):e456-e462.

E

Nguyen A, Rossi S, Croteau D, Best BM, Clifford DB, Collier AC, Gelman B, Marra C, McArthur JC, McCutchan JA, et al. Etravirine in CSF is highly protein bound. J Antimicrob Chemother. 2013 ;68(5):1161-8.

G

Pillai SK, Pond SLK, Liu Y, Good BM, Strain MC, Ellis RJ, Letendre S, Smith DM, Günthard HF, Grant I, et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain: A Journal of Neurology [Internet]. 2006 ;129:1872-83. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16735456

I

Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, Song IH, Piscitelli SC. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis. 2014 ;59(7):1032-7.

L

Fazeli PL, Moore DJ, Franklin DR, Umlauf A, Heaton RK, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor NC, et al. Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia. Curr HIV Res. 2016 ;14(4):324-30.

M

Ubaida-Mohien C, Lamberty B, Dickens AM, Mielke MM, Marcotte TD, Sacktor N, Grant I, Letendre S, Franklin D, Cibrowski P, et al. Modifications in acute phase and complement systems predict shifts in cognitive status of HIV-infected patients. AIDS. 2017 ;31(10):1365-1378.

Kamat A, Lyons JL, Misra V, Uno H, Morgello S, Singer EJ, Gabuzda D. Monocyte Activation Markers in Cerebrospinal Fluid Are Associated with Impaired Neurocognitive Testing in Advanced HIV Infection. In: AAN Meeting. AAN Meeting. New Orleans, Louisiana; 2012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22569268

P

Anderson AM, Harezlak J, Bharti A, Mi D, Taylor MJ, Daar ES, Schifitto G, Zhong J, Alger JR, Brown MS, et al. Plasma and Cerebrospinal Fluid Biomarkers Predict Cerebral Injury in HIV-Infected Individuals on Stable Combination Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2015 ;69(1):29-35.

Bryant AK, Moore DJ, Burdo TH, Lakritz JR, Gouaux B, Soontornniyomkij V, Achim CL, Masliah E, Grant I, Levine AJ, et al. Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. AIDS. 2017 ;31(7):973-979.

R

Monteiro de Almeida S, Letendre S, Zimmerman J, Kolakowski S, Lazzaretto D, McCutchan JA, Ellis RJ. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy. Journal of Neuroimmunology [Internet]. 2006 ;179:180-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16901548

Thames AD, Briones MS, Magpantay LI, Martinez-Maza O, Singer EJ, Hinkin CH, Morgello S, Gelman BB, Moore DJ, Heizerling K, et al. The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients. AIDS. 2015 ;29(12):1483-91.